Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients
Status:
Completed
Trial end date:
2020-03-21
Target enrollment:
Participant gender:
Summary
This study is being conducted in order to assess the need for dose adjustment for elafibranor
in participants with renal impairment. Pharmacokinetic parameters of elafibranor and its
active metabolite (GFT1007) will be compared in severe renal impaired participants
(eGFR<15mL/mn/1.73m^2) versus healthy participants after a single oral administration of
elafibranor 120 mg